BV300

Product

Last mentioned: Mar 18, 2026

Timeline

  1. 2025 Earnings Release

    BioVersys officially reports 2025 financial results and corporate highlights.

  2. AlpE Phase 2b Milestone

    First patient dosed in the Phase 2b clinical trial of AlpE for pulmonary tuberculosis.

  3. Reporting Announcement

    Company announces date for full-year 2025 results and business update.

  4. Fiscal Year End

    BioVersys concludes its 2025 fiscal year with key pipeline advancements.

Stories mentioning BV300 1

pharma Neutral

BioVersys Advances AMR Pipeline with Phase 2b Milestone and 2025 Results

BioVersys AG reported its full-year 2025 financial results, highlighting the successful transition of its lead candidate AlpE into Phase 2b clinical trials for pulmonary tuberculosis. The company's progress underscores its leadership in the antimicrobial resistance (AMR) space as it moves toward late-stage clinical validation.

2 sources